NK3受体抗剂改变了经期更年期冲的中央控制感知 - 一项试点研究
Jenifer Sassarini1, Karolina Skorupskaite2, John McLean3
1College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
概括
神经基因3受体 (NK3R) 抗剂MLE4901通过降低大脑活动在insula. 这种NK3R抗剂通过改变中枢神经系统路径,显示出治疗热的前途.
科学领域:
- 神经内分泌学神经内分泌学
- 神经成像是一种神经成像.
- 热调节 热调节 热调节
背景情况:
- 基斯佩丁/神经素/丁诺芬 (KNDy) 信号传递整合了生殖和温度调节功能.
- 神经基因3受体 (NK3R) 抗剂在缓解更年期冲方面表现有前途.
- 脑干和脑岛活动与热的产生和感知有关.
研究的目的:
- 通过使用功能磁共振成像 (fMRI) 调查NK3R对抗剂MLE4901在发热期间对大脑活动的中心影响.
- 为了检查NK3R抗剂治疗的反应,突出网络内的功能连接性变化.
主要方法:
- 经过绝经后有热的5名女性接受了基线fMRI并完成了冲洗日记.
- 参与者接受了7天的NK3R抗剂MLE4901.1.治疗.
- 治疗后进行重复fMRI和冲洗日记,通过胸部监视器监测客观冲洗.
主要成果:
- MLE4901显著降低了主观热冲动频率 (平均每天6.9~1.1次).
- 没有观察到客观冲洗指标的显著变化.
- 用MLE4901治疗导致右前胰岛的功能连接性下降,与减少的主观冲相关.
结论:
- 这项试点研究表明,NK3R抗剂治疗改变了突出网络连接.
- 降低右前胰岛连接可能是NK3R对抗剂对冲血的治疗作用的关键机制.
- 需要进一步的研究,以在更大的研究中探索这些发现,并阐明其确切的作用机制.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
146
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
146
Cholinergic Antagonists: Pharmacological Actions
751
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
751
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Cholinergic Antagonists: Pharmacokinetics
395
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
395
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
600
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
600


